In 2022, the FDA approved the first combined GIP and GLP-1RA for the treatment of adults with type 2 diabetes (T2DM), with initial studies demonstrating superiority in both glycemic control and weight loss compared to GLP1-RA alone10. This evidence concerns the gene GIP and type 2 diabetes mellitus.